Overview

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

Status:
COMPLETED
Trial end date:
2024-06-26
Target enrollment:
Participant gender:
Summary
This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Calico Life Sciences LLC
Collaborator:
AbbVie
Treatments:
Moxifloxacin